#USA #Atlanta #biopharmaceuticals #Airway Therapeutics #Zelpultide Alfa

Airway Therapeutics Secures Funding for Critical Clinical Trials

On August 25, 2026, Airway Therapeutics, Inc., a biopharmaceutical company with a focus on advanced clinical trials, announced the successful closure of a $50 million funding round to support the ongoing development of zelpultide alfa. This innovative recombinant human surfactant protein D (rhSP-D) is part of a critical effort aimed at preventing bronchopulmonary dysplasia (BPD) in extremely preterm infants—a condition that has no approved preventive treatments as of yet.

Funding Breakdown

The funding comprised $26 million raised initially through a SAFE financing round and an additional $24 million from the Series E-2 round. Notably, around 94% of current investors participated in this latest funding endeavor, highlighting their confidence in the company's vision and progress. Participating investors included the Cincinnati Children's Hospital Medical Center and a consortium of prominent family offices, all committed to advancing innovative therapies for severe respiratory diseases.

Importance of Zelpultide Alfa

Zelpultide alfa stands out as a potential game changer in the landscape of neonatal care. This recombinant protein has been meticulously designed to mimic the native structure and biological function of the human surfactant protein D, enhanced through advanced cell line technology. Clinical trials so far suggest that zelpultide alfa works through three main mechanisms: modulating immune responses to reduce excessive inflammation, improving pathogen recognition and clearance, and maintaining surfactant homeostasis to support pulmonary function.

The primary focus of ongoing clinical development is to prevent bronchopulmonary dysplasia among extremely premature infants, marking a significant step forward in treating a high-risk population with unmet medical needs.

Clinical Trials Progress

As part of the ongoing Phase 2b/3 clinical trial, which seeks to confirm the efficacy and safety of zelpultide alfa, an interim analysis is anticipated by the end of the second quarter in 2027. This analysis will conclude the Phase 2b portion of the trial and is expected to provide critical insights into the drug's potential to mitigate BPD in vulnerable populations.

Alan S. Wolk, CFO and COO of Airway Therapeutics, emphasized the financial fortitude this funding brings. He stated, “This financing enables us to rigorously advance zelpultide alfa toward later-stage development, ensuring the clinical study and necessary analyses are well-supported.”

Future Outlook

Airway Therapeutics is well-positioned for continued growth, both in its current clinical endeavors and in the exploration of wider applications for zelpultide alfa across different age groups and conditions. Given the promising safety profile evidenced in Phase 1b studies, the company aims to transform the standard of care for patients confronted with acute and chronic respiratory, inflammatory, and infectious diseases.

For further information about Airway Therapeutics and ongoing clinical projects, please visit their official website at Airway Therapeutics.